Winship Cancer Insititute of Emory University
Welcome,         Profile    Billing    Logout  
 5 Trials 
14 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
NGuyen, Kim
RA-PROPR, NCT04692493: RA-PRO PRAGMATIC TRIAL

Recruiting
3
924
Canada, US
targeted synthetic DMARD class, non-TNFi-biologic class
University of Alabama at Birmingham, Patient-Centered Outcomes Research Institute
Rheumatoid Arthritis
02/27
12/28
TREOCAPA, NCT04459117 / 2019-004297-26: Prophylactic Treatment of the Ductus Arteriosus in Preterm Infants by Acetaminophen

Active, not recruiting
2/3
824
Europe
Acetaminophen, NACL 0.9%
Institut National de la Santé Et de la Recherche Médicale, France, UPCET, PARTNERS for International clinical Research, European Fundation for the Care of the Newborn Infants, Connect for Children
Patency of the Ductus Arteriosus, Acetaminophen, Extreme Prematurity
07/24
07/24
NCT05894707: Evaluate the Safety and Tolerability of SCT650C in Healthy Volunteers

Not yet recruiting
1
32
RoW
SCT650C, Recombinant anti-IL-17A antibody
Sinocelltech Ltd.
Autoimmune Disease
11/23
03/24
RECCLAIM-II, NCT03804060: REperfusion With Cooling in CerebraL Acute IscheMia II

Completed
N/A
90
US
Thermogard XP3, Recanalization only
ZOLL Circulation, Inc., USA
Ischemic Stroke
05/24
05/24
TREOCAPA-LT, NCT06064825: Long Term Follow-up of the TREOCAPA Study

Recruiting
N/A
500
Europe
2 year follow-up of neurodevelopment using a parental questionnaire
Institut National de la Santé Et de la Recherche Médicale, France
Patency of the Ductus Arteriosus Acetaminophen Extreme Prematurity
12/26
06/27
IntoxPara, NCT04850014: PBPK Modelling Applied to Acetaminophen Poisoned Obese Children

Recruiting
N/A
300
Europe
Anthropomorphism, Relevant clinical datas
Hospices Civils de Lyon
Poisoning, Obesity
05/21
10/21
Akce, Mehmet
NCT05199285: A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab

Recruiting
2
40
US
Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Nivolumab, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo
Academic and Community Cancer Research United, National Cancer Institute (NCI)
BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Locally Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
01/24
01/27
NCT05103904: Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant

Recruiting
2
19
US
Laboratory Biomarker Analysis, Lenvatinib, E7080, ER-203492-00, Multi-Kinase Inhibitor E7080
Emory University, National Cancer Institute (NCI), Eisai Co., Ltd.
Recurrent Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC V8, Stage IIIA Hepatocellular Carcinoma AJCC V8, Stage IIIB Hepatocellular Carcinoma AJCC V8, Stage IV Hepatocellular Carcinoma AJCC V8, Stage IVA Hepatocellular Carcinoma AJCC V8, Stage IVB Hepatocellular Carcinoma AJCC V8, Unresectable Hepatocellular Carcinoma
11/25
11/26
NCT05194293: Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer

Recruiting
2
30
US
Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Regorafenib, BAY 73-4506, Regorafenib Anhydrous
Academic and Community Cancer Research United, National Cancer Institute (NCI)
Stage IB Hepatocellular Carcinoma AJCC v8, Stage II Hepatocellular Carcinoma AJCC v8, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8
12/24
12/28
TAPUR, NCT02693535: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Recruiting
2
3791
US
Palbociclib, Ibrance, Sunitinib, Sutent, Temsirolimus, Torisel, Trastuzumab and Pertuzumab, Herceptin and Perjeta, Vemurafenib and Cobimetinib, Zelboraf and Cotellic, Regorafenib, Stivarga, Olaparib, Lynparza, Pembrolizumab, Keytruda, Nivolumab and Ipilimumab, Opdivo and Yervoy, Abemaciclib, Verzenio, Talazoparib, Talzenna, Atezolizumab and PHESGO, Tecentriq and PHESGO, Atezolizumab and Talazoparib, Tecentriq and Talzenna, Entrectinib, Rozlytrek, Larotrectinib, Vitrakvi, Tucatinib plus Trastuzumab Subcutaneous (SC), Tukysa and Herceptin Hylecta, Futibatinib, Lytgobi
American Society of Clinical Oncology, AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Inc., Merck Sharp & Dohme LLC, Pfizer, Boehringer Ingelheim, Seagen Inc., Taiho Oncology, Inc.
Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
06/26
06/27
NCT06728410: A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement

Not yet recruiting
2
38
US
Pemigatinib, PEMAZYRE, Durvalumab, Imfinzi
Mehmet Akce, AstraZeneca, Incyte Corporation, University of Alabama at Birmingham
Intrahepatic Cholangiocarcinoma, FGFR2 Gene Rearrangement, FGFR2 Gene Mutation
07/26
07/27
NCT06294548: A Study of Valemetostat Tosylate (DS-3201b) with Atezolizumab and Bevacizumab in HCC

Not yet recruiting
1/2
45
US
Valemetostat, Valemetostat tosylate, Valemetostat (DS-3201), Atezolizumab, Bevacizumab
University of Alabama at Birmingham
Hepatocellular Carcinoma
12/27
07/28
NCT04650451: Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors

Suspended
1/2
220
US
chimeric antigen receptor (CAR) T cell therapy, CAR-T, BPX-603, autologous CAR-T
Bellicum Pharmaceuticals
HER-2 Gene Amplification, HER2-positive Gastric Cancer, HER2-positive Breast Cancer, HER-2 Protein Overexpression, Solid Tumor, Adult
12/25
01/27
NCT06182072: ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)

Recruiting
1
28
US
ProAgio Dose Levels (DL) 1,2,3,4, ACT50, Gemcitabine, nab paclitaxel, (G-nP)
ProDa BioTech, LLC, University of Alabama at Birmingham, Georgia State University
Pancreatic Ductal Carcinoma
07/25
10/25

Download Options